Cargando…
Tumour treating fields therapy for glioblastoma: current advances and future directions
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophys...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884384/ https://www.ncbi.nlm.nih.gov/pubmed/33144698 http://dx.doi.org/10.1038/s41416-020-01136-5 |
_version_ | 1783651403503239168 |
---|---|
author | Rominiyi, Ola Vanderlinden, Aurelie Clenton, Susan Jane Bridgewater, Caroline Al-Tamimi, Yahia Collis, Spencer James |
author_facet | Rominiyi, Ola Vanderlinden, Aurelie Clenton, Susan Jane Bridgewater, Caroline Al-Tamimi, Yahia Collis, Spencer James |
author_sort | Rominiyi, Ola |
collection | PubMed |
description | Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields. |
format | Online Article Text |
id | pubmed-7884384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78843842021-06-11 Tumour treating fields therapy for glioblastoma: current advances and future directions Rominiyi, Ola Vanderlinden, Aurelie Clenton, Susan Jane Bridgewater, Caroline Al-Tamimi, Yahia Collis, Spencer James Br J Cancer Review Article Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields. Nature Publishing Group UK 2020-11-04 2021-02-16 /pmc/articles/PMC7884384/ /pubmed/33144698 http://dx.doi.org/10.1038/s41416-020-01136-5 Text en © The Author(s) 2020, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Rominiyi, Ola Vanderlinden, Aurelie Clenton, Susan Jane Bridgewater, Caroline Al-Tamimi, Yahia Collis, Spencer James Tumour treating fields therapy for glioblastoma: current advances and future directions |
title | Tumour treating fields therapy for glioblastoma: current advances and future directions |
title_full | Tumour treating fields therapy for glioblastoma: current advances and future directions |
title_fullStr | Tumour treating fields therapy for glioblastoma: current advances and future directions |
title_full_unstemmed | Tumour treating fields therapy for glioblastoma: current advances and future directions |
title_short | Tumour treating fields therapy for glioblastoma: current advances and future directions |
title_sort | tumour treating fields therapy for glioblastoma: current advances and future directions |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884384/ https://www.ncbi.nlm.nih.gov/pubmed/33144698 http://dx.doi.org/10.1038/s41416-020-01136-5 |
work_keys_str_mv | AT rominiyiola tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections AT vanderlindenaurelie tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections AT clentonsusanjane tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections AT bridgewatercaroline tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections AT altamimiyahia tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections AT collisspencerjames tumourtreatingfieldstherapyforglioblastomacurrentadvancesandfuturedirections |